Erythromycin is a macrolide antibiotic that has an antimicrobial spectrum similar to or slightly wider than that of penicillin, and is often used for people who have an allergy to penicillins. For respiratory tract infections, it has better coverage of atypical organisms, including mycoplasma and Legionellosis. Erythromycin is an antibiotic produced from a strain of Streptomyces erythraeus.
Antibiotic resistance in bottlenose dolphins shows that up to 88% of pathogenic organisms in this species is resistant to one or more antibiotics. This finding offers very useful insights into the identical phenomenon in humans. This species is termed a sentinel species, which means it reflects environmental risks to humans in advance of their occurrence in humans.
The River Thames is rapidly becoming a breeding pool for antibiotic-resistant bacteria, according to a new study, which underlines the urgent need to cut down the amount of antibiotics currently being discharge into the river by at least 80% to arrest this trend.
A new study led by researchers at Indiana University has found that women and older adults who use multiple prescription drugs are significantly more likely to be prescribed pills whose combination produces dangerous side effects.
Central London's freshwater sources contain high levels of antibiotic resistant genes, with the River Thames having the highest amount, according to research by UCL.
A JRC report brings together data on antibiotic levels in water, showing that small concentrations have found their way into a range of Europe's waterbodies.
A scientific team from Case Western Reserve University School of Medicine and Cleveland Clinic has developed a new way to identify second-line antibiotics that may be effective in killing germs already resistant to a first-line antibiotic - potentially helping overcome antibiotic resistance.
A University of Illinois team of researchers led by chemistry professor M. Christina White has developed a new manganese-based catalyst that can change the structure of druglike molecules to make new drugs, advancing the pace and efficiency of drug development.
Vertex Pharmaceuticals Incorporated today announced the U.S. Food and Drug Administration approved KALYDECO® (ivacaftor) to include use in children with cystic fibrosis ages 12 to <24 months who have at least one mutation in their cystic fibrosis transmembrane conductance regulator gene that is responsive to KALYDECO based on clinical and/or in vitro assay data.
A recent study has found that changes in microbial communities within the reproductive tract of pregnant women were strongly linked to premature birth.
Changes to the communities of microbes living in the reproductive tract of pregnant women could help to spot those at risk of giving birth prematurely.
Findings from a study that looked at susceptibility trends of Staphylococcus aureus in U.S. hospital patients showed that key antibiotics used to treat the bacteria became more active over the course of the study, a rare occurrence.
Two Swiss research teams from the University of Bern and the ETH Zurich have developed a new method to shed light onto a mostly unknown process of bacterial protein production. Their results could be used for the design of new antibiotics.
The discovery of a chemical compound that halts the production of a small set of proteins while leaving general protein production untouched suggests a new drug search strategy: Find compounds that target undesired proteins before they are even made.
Researchers from North Carolina State University have discovered a way to make pinpoint changes to an enzyme-driven "assembly line" that will enable scientists to improve or change the properties of existing antibiotics as well as create designer compounds.
Microbes have long been an invaluable source of new drugs. And to find more, we may have to look no further than the ground beneath our feet.
Harvard researchers have created a new, greatly simplified, platform for antibiotic discovery that may go a long way to solving the crisis of antibiotic resistance.
Boehringer Ingelheim today announced that both the U.S. Food and Drug Administration and the European Medicines Agency have accepted filing applications for afatinib for the treatment of patients with advanced squamous cell carcinoma (SCC) of the lung progressing after treatment with first-line chemotherapy.
In a discovery with implications for future drug design, scientists from the Florida campus of The Scripps Research Institute have shown an unprecedented mechanism for how a natural antibiotic with antitumor properties incorporates sulfur into its molecular structure, an essential ingredient of its antitumor activity.
Helsinn, the Swiss Group focused on building quality cancer care, announces today that on 27th May 2015, the European Commission (EC) approved Akynzeo® (netupitant-palonosetron) for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cisplatin-based cancer chemotherapy and moderately emetogenic cancer chemotherapy in the European Union.
Boehringer Ingelheim today announced overall survival (OS) results from the LUX-Lung 8 trial (NCT01523587) that directly compared the efficacy and safety of two EGFR-directed treatments, afatinib and erlotinib, in patients with advanced squamous cell carcinoma (SCC) of the lung, progressing after treatment with first-line chemotherapy. Treatment with afatinib significantly reduced the risk of death by 19%, extending the survival of patients to a median of 7.9 months compared to 6.8 months on erlotinib.